Ticker Details
Krystal Biotech, Inc. Krystal Biotech Inc is a biopharmaceutical company. It uses gene therapy treatments for patients suffering from rare debilitating disorders.
IPO Date:	September 20, 2017
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$8.87B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$2.14 | 2.69%
Avg Daily Range (30 D):	$5.47 | 1.86%
Avg Daily Range (90 D):	$4.95 | 1.79%

Institutional Daily Volume
Avg Daily Volume:	.16M
Avg Daily Volume (30 D):	.23M
Avg Daily Volume (90 D):	.21M

Trade Size
Avg Trade Size (Sh.):	41
Avg Trade Size (Sh.) (30 D):	23
Avg Trade Size (Sh.) (90 D):	25

Institutional Trades
Total Institutional Trades:	2,344
Avg Institutional Trade:	$4.36M
Avg Institutional Trade (30 D):	$8.64M
Avg Institutional Trade (90 D):	$9.6M
Avg Institutional Trade Volume:	.03M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$5.53M
Avg Closing Trade (30 D):	$10.61M
Avg Closing Trade (90 D):	$11.03M
Avg Closing Volume:	41.17K

News

Apr 30, 2026 @ 12:00 PM Krystal Biotech to Present at Upcoming Scientific ... Source: Na

Apr 16, 2026 @ 7:26 PM Is Vertex Pharmaceuticals' Empire in Trouble? Source: Prosper Junior Bakiny

Mar 16, 2026 @ 8:00 PM What to Know About This Obesity Drug Developer Tha... Source: Jonathan Ponciano

Feb 22, 2026 @ 6:12 PM Nurix Stock Is Down 6% This Past Year, but One Bio... Source: Jonathan Ponciano

Feb 18, 2026 @ 10:17 PM Stock Market Today, Feb. 18: ImmunityBio Soars Aft... Source: Josh Kohn-Lindquist

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$7.75	$1.91	$1.77
Diluted EPS	$7.48	$1.83	$1.7
Revenue	$417.3M	$116.36M	$107.11M
Gross Profit
Net Income / Loss	$225.03M	$55.93M	$51.4M
Operating Income / Loss	$178.64M	$53.69M	$44.27M
Cost of Revenue
Net Cash Flow	$192.54M	$5.01M	$103.7M
PE Ratio